Verrica Pharmaceuticals (VRCA) investor relations material

Executive summary

• Achieved strong commercial momentum for YCANTH, with dispensed applicator units up 28.3% sequentially and 46.1% year-over-year, reaching 19,626 in Q2 2026, driven by improved prescriber targeting and patient access initiatives.

• Announced a non-dilutive credit facility of up to $27.5 million from the largest shareholder, extending cash runway into 2028 and supporting ongoing development and commercialization efforts.

• Revenue for Q2 2026 was $5.9 million, down from $12.7 million in Q2 2025 due to lower milestone payments, despite higher product sales volume.

• Net loss for Q2 2026 was $13.2 million, compared to net income of $0.2 million in Q2 2025, reflecting increased R&D and SG&A expenses and a $1.7 million legal settlement expense.

• Cash as of June 30, 2026, was $11.2 million, with an accumulated deficit of $347.7 million; substantial doubt exists about the ability to continue as a going concern without additional funding.

Financial highlights

• Q2 2026 total revenue was $5.9 million, including $5.1 million U.S. YCANTH net product revenue and $0.8 million license/collaboration revenue.

• Gross product margin was 91.5%, slightly down from 92.5% in Q2 2025; cost of product revenue was $0.4 million.

• GAAP net loss was $13.2 million ($0.62/share) versus net income of $0.2 million ($0.02/share) in Q2 2025; non-GAAP net loss was $10.2 million ($0.48/share) versus non-GAAP net income of $1.2 million ($0.12/share) in Q2 2025.

• R&D expenses rose to $6.0 million in Q2 2026 from $1.8 million in Q2 2025, mainly due to the common warts program.

• SG&A expenses were $10.3 million in Q2 2026, up from $8.9 million in Q2 2025, reflecting increased commercial investment and sales force expansion.

Outlook and guidance

• Cash runway expected to extend into 2028 with full access to the new credit facility.

• Top-line data from the global Phase 3 program for common warts anticipated in mid-2027.

• The company plans to expand its U.S. sales force to 50 representatives by year-end 2026.

• Continued focus on expanding YCANTH’s label to include common warts and advancing VP-315 for basal cell carcinoma.

• Management expects continued operating losses and will seek further capital through equity, debt, or partnerships.